Recently, our hospital's scientific research efforts have achieved momentous news! The clinical research paper co-authored by Dr. Wang Ye, Attending Physician, and Dr. Huang Deliang, Chief Physician, from the Department of Minimally Invasive Intervention, has been officially published in the international professional journal Proceedings of Anticancer Research (Volume 9, Issue 5, 2025).

The article, titled "Zorifertinib for EGFR-mutant Non-small Cell Lung Cancer after Leptomeningeal Metastasis on Double-Dose Third-generation EGFR-TKI: A Case Report and Literature Review," addresses the clinical challenge of leptomeningeal metastasis in EGFR-mutant NSCLC following resistance to third-generation EGFR-TKIs. Through a successful case study, it validates a novel therapeutic approach combining Zorifertinib and Fumotinib, highlighting its synergistic advantages of "systemic tumor suppression" and "high blood-brain barrier penetration," thereby providing an effective reference for diagnosis and treatment practices in this field.

The recognition of this research finding by an authoritative international journal marks a significant step forward for Guangzhou Royal Lee Cancer Hospital in the field of clinical oncology research. In the future, our hospital will continue to be guided by clinical needs, deepen scientific innovation, and transform research outcomes into superior diagnostic and therapeutic solutions, offering more precise and effective medical services to our patients.